Clinical Trial Update: p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating p53-adjusted neoadjuvant chemotherapy for potentially resectable esophageal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Snippet

Sponsor: Daniela Kandioler | Conditions: Esophageal Cancer | Phase 3 | Status: COMPLETED